68% Obefazimod Remission at Week 144 and €491.6M Cash Runway into Q4 2027
After two to four years at 50 mg, 130 ulcerative colitis patients de-escalated to 25 mg obefazimod, achieving 68% clinical remission at week 144 with 80% completion. Abivax ended March 31, 2026 with €491.6 million cash and short-term investments, providing a runway into Q4 2027.
1. First Quarter Financial Results
In Q1 2026 Abivax reported cash, cash equivalents and short-term investments of €491.6 million, reflecting a cash runway into Q4 2027 under current operating assumptions. Research and development expenses increased by €10.2 million to €49.5 million, driven by new indications and clinical trial progression, while general and administrative costs fell to €6.3 million.
2. Three-Year Interim Study 108 Results
Study 108’s open-label extension enrolled 130 ulcerative colitis patients who de-escalated from 50 mg to 25 mg obefazimod after two to four years of treatment. At week 144, 68% of the intent-to-treat population were in clinical remission and 80% completed the full 144-week evaluation, with no new safety signals observed.
3. Trial Updates and Cash Runway
Abivax expects Phase 3 maintenance trial results in late Q2 2026, reinforcing obefazimod’s clinical profile. The combination of durable long-term remission data and €491.6 million in liquidity supports ongoing development and potential commercial launch.